Acetaminophen or Paracetamol (Unipar (2250mg)) helps to reduce fever and to relieve a headache with mild to moderate pain. It is also used with other pain medications to treat low back pain, ...

Recurring Adjusted EBITDA: BRL1.109 billion, a 16% increase from 2024, with a margin of 22%. Net Profit: BRL482 million for the year 2025. Operating Cash Flow: BRL1.248 billion for 2025. Cash Position ...

Earnings call Unipar reported Q3 2025 recurring adjusted EBITDA of BRL 266 million, up 14% YoY, with a 20% EBITDA margin despite falling PVC and caustic soda prices. Net income reached BRL 107 million ...

Brazilian petrochemical company Unipar Carbocloro will receive $80 million in the fourth quarter after an agreement related to the acquisition of Indupa, the company said in a securities filing on ...

SAO PAULO, June 11 (Reuters) - Brazilian chemical company Unipar Carbocloro has made a non-binding offer to conglomerate Novonor for the indirect acquisition of a controlling stake in petrochemical ...

The average one-year price target for Unipar Carbocloro S.A. - Preferred Stock (BOVESPA:UNIP6) has been revised to R$74.97 / share. This is an increase of 17.60% from the prior estimate of R$63.75 ...

Brazilian petrochemicals giant Braskem SA has entered preliminary talks with Unipar Carbocloro SA to sell its US polypropylene plants at a time of weak earnings and surging debt levels, according to ...

Unipar Carbocloro SA reported a strong performance in its Q3 2025 earnings call, showcasing significant growth in EBITDA despite a challenging petrochemical market. The company achieved a recurring ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

UNIPAR ON (UNIP3) has delivered a 10.79% change over the past year, with a 52-week range between 45.82 and 68.50. What Is the Average Daily Trading Volume of UNIPAR ON (UNIP3)? The average daily ...

Adjusted EBITDA (Q4 '24): BRL472 million; excluding nonrecurring items, BRL342 million, 47% higher than Q3 '24. Net Margins (Q4 '24): BRL293 million; for the year, BRL557 million. Operating Cash ...